Kalaris Extends Cash Runway Into 2028, But TH103 Data Slips to 2H 2027
KLRS sits 29% above its 52-week low of $1.78.
Summary
Kalaris ended Q3 with $82.9M in cash and securities, down from $118.0M at year-end 2025, and now says that funds operations into 2028 — a year beyond the Q4 2027 runway it reiterated in its August 10-Q. The Q3 net loss narrowed to $11.0M from $11.9M a year ago. The tradeoff: preliminary TH103 data is now expected in 2H 2027, pushing the key clinical readout further out for a Phase 1b/2 asset, and a potential Phase 3 program is now expected in 2028. The company also completed its commercial-scale manufacturing transfer, with test batches hitting targets, though no Phase 3 supply or commercial production is reported. With a $350M shelf and $100M ATM already in place, the extended runway reduces near-term financing pressure but the delayed readout leaves little to move the stock before 2027.
At the time of this announcement, KLRS was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.2M. The 52-week trading range was $1.78 to $11.88. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.